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Abstract
Introduction Obesity has consistently been associated with
postmenopausal breast cancer risk. Proteins that are secreted
by adipose tissue or are involved in regulating body mass may
play a role in breast tumor development.
Methods We conducted a nested case-control study among
postmenopausal women from the American Cancer Society
Cancer Prevention Study II Nutrition Cohort to determine
whether genes associated with obesity increase risk for breast
cancer. Tagging single nucleotide polymorphisms (SNPs) were
selected to capture common variation across seven candidate
genes that encode adipose-related proteins: ADRB2, ADRB3,
GHRL, HSD11B1, IRS1, IRS2, and SHC1. Thirty-nine SNPs
were genotyped in 648 cases and 659 controls. Logistic
regression models were used to examine the association
between each tagging SNP and risk for breast cancer while
adjusting for matching factors and potential confounders. We
also examined whether these SNPs were associated with
measures of adult adiposity.
Results Two out of five tagging SNPs in HSD11B1  were
associated with breast cancer (rs11807619, P  = 0.006;
rs932335,  P  = 0.0001). rs11807619 and rs932335 were
highly correlated (r2 = 0.74) and, when modeled as a haplotype,
only haplotypes containing the rs932335 C allele were
associated with breast cancer. The rs932335 C allele was
associated with a nearly twofold increased risk for breast cancer
(odds ratio = 1.83, 95% confidence interval = 1.01–3.33 for C/
C versus G/G). Three of the 11 SNPs for IRS2 were associated
with breast cancer (rs4773082, P = 0.007; rs2289046, P =
0.016; rs754204, P = 0.03). When these three SNPs were
examined as a haplotype, only the haplotype that included the G
allele of rs2289046 was associated with breast cancer (odds
ratio = 0.76, 95% confidence interval = 0.63–0.92 for TGC
versus CAT). IRS2 rs2289046, rs754204, and rs12584136
were also associated with adult weight gain but only among
cases. None of the other SNPs in any gene investigated were
associated with breast cancer or adiposity.
Conclusion Our findings suggest that these tagging SNPs in
HSD11B1  and IRS2  mark regions of the genome that may
harbor risk alleles for breast cancer, and these associations are
probably independent of adiposity.
Introduction
Obesity is a leading risk factor for postmenopausal breast can-
cer. High body mass index (BMI) and adult weight gain have
consistently been associated with increased risk for breast
cancer [1-3]. This increased risk is thought to result primarily
from circulating estrogens derived from extraglandular aroma-
tization of plasma androstenedione to estrone in adipose tis-
sue [4,5]. However, adipose tissue is also an active endocrine
and metabolic organ that can have far-reaching effects on the
physiology of other tissues [2]. Therefore, proteins that are
secreted by adipose tissue or are involved in regulating body
mass may play a role in breast tumor development through
mechanisms independent from estrogen production.
BMI = body mass index; IRS = insulin receptor substrate; kb = kilobases; LD = linkage disequilibrium; OR = odds ratio; PCR = polymerase chain 
reaction; PMH = postmenopausal hormone; SNP = single nucleotide polymorphism.Breast Cancer Research    Vol 10 No 4    Feigelson et al.
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To examine whether genes that encode adiposity-related pro-
teins influence the risk for breast cancer, we conducted a
nested case control study among predominantly white, post-
menopausal women from the American Cancer Society Can-
cer Prevention Study II Nutrition Cohort. Seven candidate
genes were chosen for inclusion in this study: ADRB2,
ADRB3,  GHRL,  HSD11B1,  IRS1,  IRS2, and SHC1.
Although many more genes are related to obesity and energy
balance, we chose candidate genes that had previously been
associated with at least one measure of obesity and with risk
for breast cancer [6-10] or other cancer [11,12], or had dem-
onstrated activity in breast cancer cell lines [13-15].
Materials and methods
Study population
Cases and controls included in the present study were drawn
from the Cancer Prevention Study II Nutrition Cohort, a pro-
spective study of cancer incidence that began in 1992 and
includes approximately 184,000 US adults. The characteris-
tics of this cohort are described in detail elsewhere [16].
Blood samples were collected from a subgroup of 39,376
cohort members (n = 21,965 women) between June 1998
and June 2001. After obtaining written informed consent, a
maximum of 43 ml nonfasting whole blood was collected from
each participant and samples were separated into aliquots
and frozen in liquid nitrogen vapor phase at approximately -
130°C for long-term storage. The women who provided blood
specimens were similar to the overall population in the distri-
bution of most demographic and lifestyle characteristics. This
study has been approved by the Institutional Review Board of
Emory University and is in compliance with the Helsinki
Declaration.
Breast cancer patients (cases) were initially identified based
on responses to cancer history questions on surveys sent to
cohort participants in 1997, 1999, 2001, and 2003. These
cancers were subsequently verified through medical records,
linkage with state cancer registries, or death certificates. The
cases were matched to cancer-free (except nonmelanoma
skin cancer), female Nutrition Cohort control individuals (con-
trols) for single year of age (± 6 months), race/ethnicity (white,
African American, Hispanic, Asian, or other/unknown), and
date of blood collection (within 6 months).
Single nucleotide polymorphism selection and 
genotyping
The selection of specific single nucleotide polymorphisms
(SNPs) for this study involved several steps. The list of candi-
date SNPs was created based on the following criteria: inclu-
sion in the International HapMap Project database [17];
location within 10 kilobases (kb) of one of the candidate genes
(to capture potential regulatory regions) as well as all of the
exons and introns; and minor allele frequency of at least 5% in
a Caucasian population (to ensure sufficient power). Also
included were three nonsynonymous SNPs listed on dbSNP
[18] that were not in HapMap but had been validated and had
a minor allele frequency of above 5% in a Caucasian popula-
tion (ADRB3 rs4994, IRS1 rs1801276, and IRS2 1805097).
These criteria yielded a total of 72 SNPs among the seven
genes in this analysis. From this list, tagging were selected
using the Tagger program in Haploview (v.3.32) [19,20]. Tag-
ger is a computer program that is used to select and evaluate
tagging SNPs based on the empirical patterns of linkage dis-
equilibrium (LD) called 'bins'. This allows common variation
across the region of interest to be captured with fewer SNPs.
For this analysis, we used pair-wise tagging to choose SNPs
that were correlated at r2 equal to 0.80 or greater with all other
SNPs in a LD bin. Furthermore, we required that SNPs previ-
ously shown to be associated with cancer and nonsynony-
mous SNPs be 'forced in' as tagging SNPs. To further reduce
the number of SNPs, 27 singleton SNPs (SNPs that were not
in LD with any other SNPs) located more than 1 kb from an
exon were excluded (singleton SNPs from bins in or near to
exons were not excluded). This resulted in a total of 45 SNPs
(including the three nonsynonymous SNPs described above)
selected. Thirty-nine SNPs were successfully genotyped in the
first round. The remaining six failed after two independent
attempts, possibly because of high GC content and/or low-
complexity in the SNP region.
Genotyping was performed by the Center for Medical Genom-
ics at Emory University using the Beckman SNPstream geno-
typing system. SNPstream is designed to conduct high-
throughput, multiplex genotyping using single-base primer
extension technology in a tagged fluorescent assay. We used
a SNPstream companion primer design website [21] to
design three primers (two for PCR and one for single-base
extension) per SNP and multiplex them into 48-plex primer
panels. The PCR primers were used to amplify an approxi-
mately 100 base pair region flanking each SNP in a 384-well
PCR plate. Image processing and genotype calling were car-
ried out using the GenomeLab SNPstream Genotyping Sys-
tem Software Suite v2.3. Details of the primer sequences and
experimental protocol are available upon request.
Laboratory personnel were blinded to case-control status.
Positive and negative DNA controls were included on each
plate and 10% blind duplicates were randomly interspersed
among the case-control samples to validate genotyping proce-
dures. Concordance among duplicates samples was above
99%. The overall call rate for each genotyping assay ranged
from 87.4% to 99.6%. The two lowest call rates were for IRS2
rs2289046 (87.4%) and IRS2 rs4773092 (92.5%). We care-
fully evaluated these assays, checked the concordance of
duplicate samples, and tested for deviations from Hardy-
Weinberg equilibrium. We found no reason to exclude them
from the analysis. One SNP (ADRB2  rs1042714) was
dropped from the analysis because the allele distribution
among controls deviated from Hardy-Weinberg equilibrium (PAvailable online http://breast-cancer-research.com/content/10/4/R57
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= 0.004). No other deviations from Hardy-Weinberg equilib-
rium were observed (at the P < 0.01 level).
Statistical analysis
Unconditional logistic regression models were used to exam-
ine the association between each SNP and breast cancer
while controlling for matching factors. For each SNP, homozy-
gotes for the more common allele were used as the reference
group. Using questionnaire data collected before diagnosis,
we evaluated BMI (weight [kg]/height [m]2), adult weight
change (from age 18 years), postmenopausal hormone (PMH)
use (never, estrogen replacement therapy, combination hor-
mone therapy, or missing), family history of breast cancer
(mother or sister [s] with breast cancer), and history of breast
cysts as possible confounders. BMI and weight gain were
modeled as continuous variables. We also tested for effect
modification between the genotypes and BMI, postmenopau-
sal hormone use, family history of breast cancer, and history of
breast cysts using likelihood ratio tests. Models with the main
effect of genotype and the covariate of interest were com-
pared with models with the main effects of genotype and the
covariate of interest plus a multiplicative interaction term of the
two variables.
Among SNPs that were statistically significant and in strong
LD, we conducted haplotype analysis using the program TAG-
SNPS [22] to estimate haplotype frequencies. The TAGSNPS
program uses an expectation maximization approach to assign
haplotypes based on unphased genotype data. We used
logistic regression models with the most common haplotype
as the reference to estimate haplotype-specific odds ratios
(ORs) while controlling for matching factors and other
covariates.
Finally, we used age-adjusted linear regression models to
examine whether any of these SNPs were associated with self-
reported BMI at age 18 years, BMI in 1992, or adult weight
change. Age-adjusted means for each metric were computed
by genotype.
Results
A total of 648 cases and 659 controls were included in the
analysis. Characteristics of the study population are shown in
Table 1. The study population was 99% white, and the mean
age at breast cancer diagnosis was 68.9 years. Cases were
slightly more likely than controls to have a BMI of 30.0 kg/m2
or greater (16.4% versus 15.6%), but this difference was not
statistically significant (P  = 0.16). Cases and controls
reported similar weight change since age 18 years (27.9 lb
[12.7 kg] versus 27.1 lb [12.3 kg]; P = 0.58). It is well estab-
lished (in this cohort [23] and others [1,24]) that an interaction
exists between obesity and PMH use, in which the deleterious
effect of obesity is observed only among women not using
PMH. The apparent lack of association in this analysis can be
accounted for by this relationship. Sixty per cent of the study
population use PMH; among those women not using PMH,
obesity is associated with increased risk for breast cancer.
Figure 1 shows the log-additive P values for the association
between breast cancer and all 38 SNPs analyzed. Table 2
shows the association between breast cancer and tagging
SNPs in HSD11B1. In multivariate adjusted models, SNPs
rs11807619 and rs932335 were both associated with breast
cancer. For rs11807619, the T allele was associated with a
40% increased risk for breast cancer (OR = 1.41, 95% CI =
1.10 to 1.80 among women with any T allele versus G/G
women; P = 0.006). For rs932335, the adjusted ORs were
1.56 (95% CI = 1.22 to 2.00) for G/C and 1.83 (95% CI =
1.01 to 3.33) for C/C compared with G/G (P for trend =
0.0002). Further examination of these SNPs using Haploview
indicated that they were highly correlated (D' = 0.99 and r2 =
0.74; Figure 2). Haplotype analysis of these two SNPs
showed that rs11807619 was no longer an independent pre-
dictor of risk. The two haplotypes that carry the C allele of
rs932335 were both associated with breast cancer.
Results for IRS2 SNPs are shown in Table 3. Three of the 11
tagging SNPs for IRS2 were associated with breast cancer
(rs4773082,  P  = 0.007; rs2289046, P  = 0.016; and
rs754204, P = 0.03). The C allele of rs4773082 was associ-
ated with increased risk for breast cancer (OR = 1.41, 95% CI
= 1.10 to 1.81 for T/C and C/C versus T/T). For rs2289046
the G allele was associated with a reduced risk for breast can-
cer; the adjusted ORs were 0.79 (95% CI = 0.61 to 1.01) for
A/G and 0.52 (95% CI = 0.32 to 0.84) for G/G compared
with A/A. The T allele of rs754204 was associated with
increased risk for breast cancer (OR = 1.32, 95% CI = 1.03
to 1.70 for T/C and T/T versus C/C). These SNPs span a
region of 8.1 kb, with D' ranging from 1.0 to 0.85 and r2 rang-
ing from 0.71 to 0.42 (Figure 2). Thus, we created a haplotype
of these three SNPs. The TGC haplotype is associated with
decreased risk (P = 0.0018), and the magnitude of the effect
is similar to that of single SNP results for rs2289046.
No other SNPs in any of the other five genes were associated
with breast cancer (Figure 1 and Additional file 1), and neither
was there any evidence of effect modification by BMI, PMH
use, family history of breast cancer, or history of breast cysts
for any gene or SNP in this analysis (data not shown). None of
our results for associations with breast cancer change if BMI
is used in the model in place of weight change; adding BMI at
age 18 years also does not change any associations with
breast cancer. It should be noted that only one of the tested
SNPs (rs932335 in HSD11B1) would be statistically signifi-
cant after adjusting for multiple testing using the Bonferroni
method.
Table 4 shows mean BMI and adult weight change by geno-
type for the IRS2 SNPs separately for cases and controls. We
did not find any associations among our control women.Breast Cancer Research    Vol 10 No 4    Feigelson et al.
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Among the cases, the G allele for IRS2 rs2289046, which
was protective for breast cancer, also was associated with
less weight gain in adulthood compared to the A allele (P =
0.016). The T allele of rs754204, which was associated with
increased risk for breast cancer, was associated with greater
adult weight gain compared with the C allele (P = 0.012). The
A allele of rs12584136 was associated with greater weight
gain (P = 0.026), but was not associated with breast cancer.
Table 1
Characteristics of the breast cancer cases and controls
Variable Cases (n = 648) Controls (n = 659) P diffa
Age at blood draw (years; mean ± SD) 69.2 (5.8) 69.3 (5.76) P = 0.93
Age at diagnosis (years; mean ± SD) 68.9 (6.25) - -
BMI (kg/m2; mean ± SD) 25.2 (4.54) 25.5 (4.56) P = 0.22
Adult weight change (lb; mean ± SD) 27.9 (25.65) 27.1 (25.91) P = 0.58
Race (n [%])
White 642 (99.1) 653 (99.1) P = 0.98
Other 6 (0.9) 6 (0.9)
BMI (kg/m2; n [%])
<25 364 (56.2) 338 (51.3) P = 0.16
25–30 170 (26.2) 210 (31.9)
30+ 106 (16.4) 103 (15.6)
Missing 8 (1.2) 8 (1.2)
History of breast cysts (n [%])
No 402 (62) 460 (69.8) P = 0.003
Yes 246 (38) 199 (30.2)
Postmenopausal hormone use (n [%])
Never 213 (32.9) 255 (38.7) P < 0.0001
ERT 204 (31.5) 260 (39.5)
CHRT 203 (31.3) 120 (18.2)
Unknown 28 (4.3) 24 (3.6)
Family history of breast cancer (n [%])
No 513 (79.2) 564 (85.6) P = 0.002
Yes 135 (20.8) 95 (14.4)
Education (n [%])
<High school 7 (1.1) 25 (3.8) P = 0.0008
High school 166 (25.6) 196 (29.7)
Some college 181 (27.9) 190 (28.8)
College + 294 (45.4) 248 (37.6)
Age at menopause (years; n [%])
<40 55 (8.5) 72 (10.9) P = 0.002
40 to 44 65 (10) 85 (12.9)
45 to 49 139 (21.5) 179 (27.2)
50 to 54 301 (46.5) 258 (39.2)
55+ 88 (13.6) 65 (9.9)
aP value is a t-test for the means, and a Pearson χ2 for the frequencies. BMI, body mass index; CHRT, combined hormone replacement therapy; 
ERT, estrogen replacement therapy; SD, standard deviation.Available online http://breast-cancer-research.com/content/10/4/R57
Page 5 of 11
(page number not for citation purposes)
None of these SNPs would be statistically significant after
adjusting for multiple testing using the Bonferroni method.
None of the SNPs were associated with BMI. None of the
SNPs in any of the other genes examined, including
HSD11B1, were associated with adult weight change or BMI
(data not shown), and neither were any of the SNPs associ-
ated with self-reported BMI at age 18 years (data not shown).
Discussion
Our results suggest that common variation in HSD11B1 and
IRS2 may be associated with breast cancer among postmen-
opausal women. These associations appear to be
independent of adiposity. The HSD11B1  rs932335 minor
allele (allele frequency = 18% among controls) was associ-
ated with a nearly twofold increased risk for breast cancer (P
= 0.0002). This SNP is highly correlated with rs11807619,
and in haplotype analysis only the two common haplotypes
that carried the rs932335 C allele were associated with risk
for breast cancer. Three SNPs in IRS2 were associated with
breast cancer and were also found to be in LD (rs4773082,
rs2289046, and rs754204). When these SNPs were mod-
eled as a haplotype, the haplotype that included the G allele of
rs2289046 (allele frequency = 34% among controls) was the
only common haplotype associated with breast cancer (OR =
0.76, 95% CI = 0.63 to 0.92 for one copy of TGC versus CAT;
P = 0.0050). Thus, these tagging SNPs may mark regions of
the genome that harbor risk alleles for breast cancer.
HSD11B1 is located at 1q32-41 and encodes the enzyme
11β-hydroxysteroid dehydrogenase type 1, which converts the
inactive steroid cortisone into the active glucocorticoid corti-
sol, principally in the liver and adipose tissue [25]. To our
knowledge, HSD11B1 has not been examined previously in
any candidate gene study. However, 11 SNPs in HSD11B1
were included in a recent genome-wide scan of breast cancer
[26,27] and none were associated with breast cancer, includ-
ing SNPs that were highly correlated with ours. Two SNPs,
rs4393158 and rs2235543, included in the scan, were also
genotyped in our study with similar (negative) results.
Polymorphisms in HSD11B1 have been associated with type
2 diabetes and hypertension [25]. Recently, HSD11B1 was
identified from a genome-wide linkage analysis as a possible
candidate gene for weight change [28]. However, others [29]
have reported no association with HSD11B1 and body com-
position. HSD11B1 variation has also been associated with
polycystic ovarian syndrome [25], and ovarian steroids have
been shown to regulate 11β-hydroxysteroid dehydrogenase
expression in experimental models [13].
Figure 1
Log-additive model P values for the association between breast cancer  and 38 SNPs in seven genes Log-additive model P values for the association between breast cancer 
and 38 SNPs in seven genes. SNP, single nucleotide polymorphism.
Figure 2
Pattern of linkage disequilibrium for tagging SNPs genotyped in  HSD11B1 and IRS2 Pattern of linkage disequilibrium for tagging SNPs genotyped in 
HSD11B1 and IRS2. The gray shaded boxes correspond to the paired 
r2 between the single nucleotide polymorphisms (SNPs). The associ-
ated protein products are also shown.Breast Cancer Research    Vol 10 No 4    Feigelson et al.
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IRS2, a member of the insulin receptor substrate family, is
expressed in nearly all cells and tissues. IRS2 regulates body
weight control and glucose homeostasis [11]. Although the
primary role played by IRS2 is in insulin signaling, IRS2 can
also act as a substrate for insulin-like growth factor receptor
and thus it acts in insulin-like growth factor signal transduction.
Evidence also suggests that IRS proteins may play a role in
estrogen signaling [8]. Previous studies of IRS2 variation and
measures of adiposity have been inconsistent. Lautier and
coworkers [30] suggested that IRS2 haplotypes were associ-
ated with severe obesity (BMI ≥40 kg/m2) among French indi-
viduals, but a later report by Sweeney and colleagues [31] did
Table 2
HSD11B1 SNP and haplotype associations with breast cancer
Matching adjusteda Multivariate adjustedb
SNP Alleles Cases Controls OR (95% CI) P valuec OR (95% CI) P valuec
HSD11B1 rs4393158
G/G 563 578 1.00 (-) 1.00 (-)
G/A 65 61 1.10 (0.76–1.59) 1.09 (0.75–1.59)
A/A 2 0 - (-) 0.39 - (-) 0.44
G/A or A/A 67 61 1.14 (0.79–1.64) 0.5 1.13 (0.77–1.64) 0.55
rs17317033
A/A 502 493 1.00 (-) 1.00 (-)
A/C 100 126 0.78 (0.58–1.04) 0.77 (0.57–1.04)
C/C 9 4 2.16 (0.66–7.09) 0.37 1.75 (0.52–5.83) 0.26
A/C or C/C 109 130 0.82 (0.62–1.09) 0.18 0.80 (0.60–1.07) 0.14
rs2235543
C/C 489 510 1.00 (-) 1.00 (-)
C/T 143 128 1.17 (0.89–1.53) 1.17 (0.89–1.54)
T/T 11 13 0.88 (0.39–1.99) 0.44 0.90 (0.39–2.05) 0.44
C/T or T/T 154 141 1.14 (0.88–1.48) 0.32 1.14 (0.88–1.49) 0.33
rs11807619
G/G 419 471 1.00 (-) 1.00 (-)
G/T 197 159 1.39 (1.08–1.78) 1.41 (1.10–1.82)
T/T 22 18 1.34 (0.71–2.55) 0.012 1.37 (0.71–2.63) 0.01
G/T or T/T 219 177 1.38 (1.09–1.76) 0.008 1.41 (1.10–1.80) 0.006
rs932335
G/G 349 421 1.00 (-) 1.00 (-)
G/C 234 185 1.52 (1.20–1.94) 1.56 (1.22–2.00)
C/C 30 20 1.75 (0.98–3.15) 0.0003 1.83 (1.01–3.33) 0.0002
G/C or C/C 264 205 1.55 (1.23–1.95) 0.0002 1.59 (1.25–2.02) 0.0001
Haplotypes of rs11807619 and rs932235 GG 488.7 532.9 1.00 (-) 1.00 (-)
TC 120.3 97.3 1.35 (1.09–1.66) 0.0055 1.37 (1.11–1.70) 0.0040
GC 33.4 24.2 1.54 (1.04–2.28) 0.030 1.62 (1.08–2.41) 0.019
TG 0.6 0.6 0.89 (0.06–14.39) 0.93 0.96 (0.06–15.81) 0.98
Global P value = 0.01 Global P value = 0.006
aAdjusted for race, birth date, and blood draw date. bAdjusted for race, birth date, blood draw date, adult weight change, breast cysts, family 
history of breast cancer, and hormone replacement therapy use. cFor HSD11B1 P values are provided for the log-additive model, and the 
dominant model; for Haplotypes of rs11807619 and rs932235, haplotype P values are compared with the most common haplotype. CI, 
confidence interval; HSD11B1, 11β hydroxysteroid dehydrogenase type 1 gene; OR, odds ratio.Available online http://breast-cancer-research.com/content/10/4/R57
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Table 3
IRS2 SNP and haplotype associations with breast cancer
Matching adjusteda Multivariate adjustedb
SNP Alleles Cases Controls OR (95% CI) P valuec OR (95% CI) P valuec
IRS2 rs9515118
G/G 386 404 1.00 (-) 1.00 (-)
G/C 201 201 1.06 (0.83–1.34) 1.07 (0.83–1.37)
C/C 28 23 1.28 (0.72–2.29) 0.43 1.28 (0.70–2.31) 0.40
G/C or C/C 229 224 1.08 (0.85–1.36) 0.54 1.09 (0.86–1.38) 0.49
rs4773082
T/T 157 205 1.00 (-) 1.00 (-)
T/C 327 299 1.43 (1.10–1.86) 1.46 (1.12–1.91)
C/C 156 146 1.40 (1.03–1.91) 0.024 1.31 (0.96–1.80) 0.07
T/C or C/C 483 445 1.42 (1.11–1.82) 0.005 1.41 (1.10–1.81) 0.007
rs2289046
A/A 275 248 1.00 (-) 1.00 (-)
A/G 245 284 0.78 (0.61–0.99) 0.79 (0.61–1.01)
G/G 32 57 0.51 (0.32–0.81) 0.0018 0.52 (0.32–0.84) 0.004
A/G or G/G 277 341 0.73 (0.58–0.92) 0.009 0.74 (0.58–0.94) 0.016
rs754204
C/C 155 198 1.00 (-) 1.00 (-)
C/T 328 315 1.33 (1.02–1.73) 1.32 (1.01–1.73)
T/T 159 142 1.43 (1.05–1.94) 0.022 1.32 (0.96–1.82) 0.07
C/T or T/T 487 457 1.36 (1.06–1.74) 0.015 1.32 (1.03–1.70) 0.03
rs7987237
C/C 470 491 1.00 (-) 1.00 (-)
C/T 156 149 1.10 (0.85–1.43) 1.17 (0.90–1.53)
T/T 15 11 1.50 (0.68–3.31) 0.27 1.56 (0.70–3.50) 0.13
C/T or T/T 171 160 1.13 (0.88–1.45) 0.35 1.20 (0.93–1.55) 0.17
rs12584136
C/C 579 588 1.00 (-) 1.00 (-)
C/A 54 56 0.98 (0.66–1.44) 0.96 (0.64–1.43)
A/A 4 3 1.31 (0.29–5.88) 0.96 1.44 (0.31–6.71) 0.98
C/A or A/A 58 59 0.99 (0.68–1.45) 0.97 0.98 (0.67–1.45) 0.93
rs9559648
C/C 269 306 1.00 (-) 1.00 (-)
C/T 304 268 1.29 (1.02–1.62) 1.30 (1.03–1.65)
T/T 66 73 1.02 (0.71–1.49) 0.27 0.97 (0.66–1.42) 0.34
C/T or T/T 370 341 1.23 (0.99–1.53) 0.07 1.23 (0.98–1.54) 0.07
rs9559654
G/G 301 317 1.00 (-) 1.00 (-)Breast Cancer Research    Vol 10 No 4    Feigelson et al.
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not confirm this association among US white and Hispanic
women. Genome-wide linkage studies of obesity and BMI
have not identified IRS2 as an important locus; however, the
13q region near IRS2 showed some evidence of linkage to
BMI in a recent meta-analysis [32]. We observed modest
associations between three IRS2  SNPs and adult weight
change among our cases. Because these associations are not
seen among the controls, we suspect that these results are
due to chance. Furthermore, we do not think that the relation-
ship between IRS2 and weight change explains the associa-
tion between IRS2 SNPs and breast cancer. As shown in
Table 3, the associations between these SNPs and breast
cancer change very little, if at all, when adult weight change is
included in the multivariate models. This suggests that the
associations we observed with breast cancer are not medi-
ated through increasing adiposity.
At least two previous studies have examined whether IRS2
SNPs are associated with breast cancer, but neither found an
association [8,10]. The first study [10] sequenced coding
regions to identify variants of interest, and then examined two
IRS2 SNPs (rs4773092 and rs1805097) in a familial breast
cancer study. Slattery and coworkers [8] used a large case-
control study, including both white and Hispanic women, to
examine the association between breast cancer and
rs1805097 (G1057D), a SNP that had previously been asso-
ciated with both colon cancer [11] and obesity [30]. We did
not find an association between rs4773092 and postmeno-
pausal breast cancer, and were unable to genotype
rs1805097 because of assay failure. Data available from the
Cancer Genetic Markers of Susceptibility initiative [27] indi-
cates that one SNP in IRS2  is marginally associated with
breast cancer (rs12584136, P = 0.051). This SNP was not
associated with risk in our data. None of the other IRS2 SNPs
G/A 248 250 1.05 (0.83–1.33) 1.05 (0.82–1.34)
A/A 67 59 1.19 (0.81–1.75) 0.39 1.19 (0.80–1.76) 0.40
G/A or A/A 315 309 1.07 (0.86–1.34) 0.52 1.08 (0.86–1.35) 0.52
rs7997595
C/C 434 453 1.00 (-) 1.00 (-)
C/G 161 170 0.99 (0.77–1.28) 1.02 (0.79–1.32)
G/G 19 9 2.24 (1.00–5.01) 0.34 2.31 (1.02–5.24) 0.23
C/G or G/G 180 179 1.05 (0.82–1.35) 0.68 1.09 (0.84–1.40) 0.50
rs7981705
C/C 435 470 1.00 (-) 1.00 (-)
C/T 190 164 1.25 (0.98–1.60) 1.17 (0.91–1.51)
T/T 17 19 0.99 (0.50–1.93) 0.16 0.90 (0.45–1.79) 0.43
C/T or T/T 207 183 1.23 (0.97–1.56) 0.09 1.14 (0.89–1.46) 0.29
rs4773092
G/G 152 170 1.00 (-) 1.00 (-)
G/A 333 303 1.24 (0.95–1.62) 1.21 (0.92–1.60)
A/A 132 118 1.28 (0.92–1.78) 0.12 1.30 (0.93–1.82) 0.11
G/A or A/A 465 421 1.25 (0.97–1.62) 0.08 1.24 (0.95–1.61) 0.11
Haplotypes of rs4773082, rs2289046, and 
rs754204
CAT 296.8 273.2 1.00 - 1.00 -
TGC 188.8 227.4 0.74 (0.62–0.90) 0.0018 0.76 (0.63–0.92) 0.0050
TAC 107.3 104.6 0.99 (0.78–1.24) 0.89 1.04 (0.82–1.32) 0.75
Other groups 52.2 49.9 0.98 (0.72–1.33) 0.88 0.96 (0.70–1.32) 0.80
Global P value = 0.015 Global P value = 0.030
aAdjusted for race, birth date, and blood draw date. bAdjusted for race, birth date, blood draw date, adult weight change, breast cysts, family 
history of breast cancer, and hormone replacement therapy use. cFor IRS2 P values are provided for the log-additive model, and the dominant 
model; for Haplotypes of rs4773082, rs2289046, and rs754204, haplotype P values are compared with the most common haplotype. CI, 
confidence interval; IRS2, insulin receptor substrate 2 gene; OR, odds ratio.
Table 3 (Continued)
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Table 4
Mean body mass index and adult weight change by IRS2 SNPs
IRS2 SNP Cases Controls
BMI Adult weight changea BMI Adult weight changea
Mean (SE) Mean (SE) Mean (SE) Mean (SE)
rs9515118 G/G 24.98 (0.23) 26.92 (1.33) 25.48 (0.22) 26.48 (1.29)
G/C 25.66 (0.32) 30.94 (1.85) 25.57 (0.32) 27.6 (1.83)
C/C 25.23 (0.85) 25.36 (4.90) 25.57 (0.98) 33.07 (5.64)
P trend 0.16 0.29 0.82 0.31
rs4773082 T/T 25.41 (0.37) 26.56 (2.11) 25.12 (0.32) 25.87 (1.81)
T/C 25.2 (0.25) 27.81 (1.44) 25.64 (0.27) 27.43 (1.51)
C/C 25.17 (0.37) 29.77 (2.07) 25.8 (0.38) 28.07 (2.16)
P trend 0.64 0.28 0.15 0.42
rs2289046 A/A 25.49 (0.28) 30.71 (1.55) 25.54 (0.29) 27.5 (1.65)
A/G 24.97 (0.29) 26.09 (1.66) 25.52 (0.27) 27.06 (1.52)
G/G 25.18 (0.82) 22.46 (4.60) 24.98 (0.60) 22.68 (3.39)
P trend 0.28 0.016 0.53 0.31
rs754204 C/C 24.99 (0.37) 24.42 (2.10) 25.13 (0.32) 25.45 (1.84)
C/T 25.2 (0.25) 27.65 (1.43) 25.57 (0.26) 27.39 (1.46)
T/T 25.55 (0.36) 31.77 (2.04) 25.9 (0.38) 28.38 (2.18)
P trend 0.28 0.012 0.12 0.29
rs7987237 C/C 25.17 (0.21) 28.3 (1.20) 25.58 (0.21) 27.24 (1.17)
C/T 25.44 (0.37) 26.95 (2.09) 25.24 (0.38) 25.89 (2.13)
T/T 25.1 (1.18) 25.73 (6.66) 25.51 (1.44) 34.45 (8.16)
P trend 0.62 0.51 0.48 0.94
rs12584136 C/C 25.16 (0.19) 27.36 (1.08) 25.54 (0.19) 27.02 (1.07)
C/A 26.36 (0.63) 35.86 (3.56) 24.97 (0.61) 25.58 (3.49)
A/A 25.52 (2.28) 34.05 (12.85) 30.06 (2.60) 57.32 (14.83)
P trend 0.1 0.026 0.95 0.61
rs9559648 C/C 25.34 (0.28) 27.65 (1.59) 25.38 (0.26) 26.05 (1.48)
C/T 25.26 (0.26) 28.86 (1.49) 25.61 (0.28) 27.84 (1.59)
T/T 24.61 (0.57) 25.55 (3.20) 25.64 (0.53) 27.16 (3.02)
P trend 0.34 0.87 0.54 0.53
rs9559654 G/G 25.05 (0.26) 26.14 (1.49) 25.68 (0.26) 27.39 (1.46)
G/A 25.2 (0.29) 28.47 (1.64) 25.19 (0.29) 26.63 (1.64)
A/A 25.74 (0.56) 31.38 (3.15) 25.64 (0.59) 25.8 (3.36)
P trend 0.3 0.1 0.47 0.62
rs7997595 C/C 25.38 (0.22) 29.46 (1.25) 25.39 (0.21) 26.26 (1.21)
C/G 24.83 (0.36) 25.5 (2.05) 25.83 (0.35) 28.77 (2.00)
G/G 25.58 (1.04) 25.76 (5.94) 25.91 (1.58) 33.47 (9.08)
P trend 0.38 0.11 0.27 0.2Breast Cancer Research    Vol 10 No 4    Feigelson et al.
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genotyped in Cancer Genetic Markers of Susceptibility were
associated with breast cancer, including those that were
highly correlated with SNPs in our study.
It should be noted that we might have missed an association
with breast cancer and the 27 singleton SNPs that we
excluded from this study. Seven of these were in HSD11B1,
six each in ADRB2 and IRS2, and four each in GHRL and
IRS1. Singleton SNPs, by definition, are not correlated with
any other SNPs that have been genotyped in the region. We
chose to exclude singleton SNPs that were not near an exon,
because we reasoned that they were likely to be less informa-
tive than SNPs that were correlated with other nearby SNPs,
or SNPs that were located in or near an exon.
The strengths of this study include the population-based
design and the use of tagging SNPs to conduct an effective
survey of the variation in these genes. The primary limitation of
this study is its relatively small sample size. Although these
data suggest that HSD11B1 and IRS2 may be associated
with risk for breast cancer, it is also possible that these find-
ings are due to chance. If these findings are confirmed in sub-
sequent studies, then additional genotyping in these regions is
warranted.
Conclusion
We conducted a nested case-control study among 648 cases
and 659 controls to determine whether germline variation in
seven genes that encode adipose-related proteins was asso-
ciated with breast cancer. Our results suggest that common
variation in HSD11B1  and  IRS2  may be associated with
breast cancer among postmenopausal white women. The
HSD11B1 rs932335 minor allele (allele frequency = 18%
among controls) was associated with a nearly twofold
increased risk for breast cancer (P = 0.0002). Three SNPs in
IRS2 were also associated with breast cancer (rs4773082,
rs2289046, and rs754204). When these SNPs were mod-
eled as a haplotype, the haplotype that included the G allele of
rs2289046 was the only common haplotype associated with
breast cancer (P = 0.0018). IRS2 rs2289046 and rs754204
were also associated with adult weight gain. No associations
with breast cancer or with adiposity were found in the other
genes included in this study: ADRB2, ADRB3, GHRL, IRS1,
and SHC1.
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